louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT06901154: Influence of the 3D-sonographic Representation of the Fetal Face on the Health-conscious Behavior of Pregnant Women
Official title: Influence of the 3D-sonographic Representation of the Fetal Face on the Health-conscious Behavior of Pregnant Women
Study type: OBSERVATIONAL
Overall status: NOT_YET_RECRUITING
Conditions: Behavior
Lead sponsor: Martin-Luther-Universität Halle-Wittenberg
Sponsor class: OTHER
First posted: 2025-03-28
Enrollment: 50
Sex: FEMALE
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: pregnant women

Brief summary: Studies have shown that ultrasound examinations during pregnancy have a short-term anxiety and stress-reducing effect, without having any influence on the mother-child bond or health-conscious behavior.

It has not yet been investigated to what extent the representation of the child's face alone achieves a lasting positive effect if the representation in 3D form were permanently available.


Eligibility criteria: Inclusion Criteria:

* pregnant women undergoing ultrasound

Exclusion Criteria:

* age \<18 years

Primary outcomes:
measure: Influence on the health-conscious behavior
timeFrame: through study completion, an average of 3 months
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
affiliation: University Hospital of Halle
name: Marcus Riemer, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT04593654: Dosing of Thromboprophylaxis and Mortality in Critically Ill COVID-19 Patients
Official title: Dosing of Thromboprophylaxis and Mortality in Critically Ill COVID-19 Patients - More Patients Included and 90-day Follow up
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Covid19
Thromboembolism
Keywords: Pulmonary embolism
Anticoagulation
Critical Care
Bleeding
Ischemic stroke
Lead sponsor: Karolinska Institutet
Sponsor class: OTHER
First posted: 2020-10-20
Enrollment: 257
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: RETROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: A cohort study of the critically ill Covid-19 patients admitted to ICU at Södersjukhuset, Stockholm from1st of March to 15 of July

Brief summary: The aim of the study is to associate dose of thromboprophylaxis with outcome in critically ill COVID-19 patients. This will be done by associating dose of thromboprophylaxis with 28-day mortality, survival outside ICU, thromboembolic event and bleeding complications.This was done in our earlier study for patients admitted in March and April (Clinicaltrials.gov NCT04412304 June 2 2020) but now we will include the patients admitted in May, June and half of July and we will ad the outcome of 90-day mortality.


Eligibility criteria: Inclusion Criteria:

* laboratory confirmed positive test for SARS-CoV-2
* admitted to ICU because of respiratory failure caused by Covid-19

Exclusion Criteria:

* patients with treatment for thromboembolic complications at arrival to the ICU
* short ICU length of stay defined as discharged the same date as ICU admission
* patients without initial thromboprophylaxis

Primary outcomes:
measure: 28-day mortality
timeFrame: 28 days from ICU-admission
Secondary outcomes:
measure: Incidence of thromboembolic events
timeFrame: 28 days from ICU-admission
measure: Incidence of bleeding events
timeFrame: 28 days from ICU-admission
measure: ICU-free days alive from ICU-admission
timeFrame: 28 days from ICU-admission
measure: 90-day mortality
timeFrame: 90 days from ICU-admission
Other outcomes:
measure: Fibrin-D-dimer levels
timeFrame: 28 days from ICU-admission
Locations:
city: Stockholm
country: Sweden
facility: Södersjukhuset
Study officials:
affiliation: Karolinska Institutet
name: Sandra Jonmarker, MD
role: PRINCIPAL_INVESTIGATOR
References:
citation: Jonmarker S, Litorell J, Dahlberg M, Stackelberg O, Everhov AH, Soderberg M, Rubenson-Wahlin R, Gunther M, Martensson J, Hollenberg J, Joelsson-Alm E, Cronhjort M. An observational study of intermediate- or high-dose thromboprophylaxis for critically ill COVID-19 patients. Acta Anaesthesiol Scand. 2022 Mar;66(3):365-374. doi: 10.1111/aas.14013. Epub 2021 Dec 16.
Clinical trial NCT01402154: EPISPOT Detection of Circulating Prostate Cells Among Adenocarcinoma Patients
Official title: The Pre-treatment Detection of Circulating, Functional, Prostate Cells Among Adenocarcinoma Patients: an Evaluation of the EPISPOT Technique
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Adenocarcinoma of the Prostate
Lead sponsor: Centre Hospitalier Universitaire de Nīmes
Sponsor class: OTHER
First posted: 2011-07-26
Enrollment: 361
Sex: MALE
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Patients with histologically proven, localized, adenocarcinoma of the prostate who accept a curative treatment.

Brief summary: The primary objective of this study is to evaluate the predictive value (in terms of remission) of a new technique for detecting circulating, functional, prostate cells among patients with localized adenocarcinoma of the prostate, and prior to any treatment.


Eligibility criteria: Inclusion Criteria:

* The patient must have given his/her informed and signed consent
* The patient must be insured or beneficiary of a health insurance plan
* Histologically proven presence of prostate adenocarcinoma
* Localized disease on digital rectal examination
* Cancer without extensions
* Acceptance of a curative treatment by the patient

Exclusion Criteria:

* The patient is participating in another study
* The patient is in an exclusion period determined by a previous study
* The patient is under judicial protection, under tutorship or curatorship
* The patient refuses to sign the consent
* It is impossible to correctly inform the patient
* The patient is taking a hormone-modifying treatment
* Patient taking adrogenic supplements

Primary outcomes:
measure: The difference between AUCs for the EPISPOT and Cellsearch Techniques
timeFrame: 1 day
Secondary outcomes:
Other outcomes:
Locations:
city: Nîmes Cedex 09
country: France
facility: CHU de Nîmes - Hôpital Universitaire Carémeau
state: Gard
city: Montpellier Cedex 05
country: France
facility: CHU de Montpellier - Hôpital Lapeyronie - Plateforme LCCRH
city: Montpellier Cedex 05
country: France
facility: CHU de Montpellier - Hôpital Lapeyronie
city: Montpellier
country: France
facility: Clinique Beau Soleil
city: Montpellier
country: France
facility: Centre Regional de Lutte Contre le Cancer - Val d'Aurelle - Paul Lamarque
Study officials:
affiliation: Centre Hospitalier Universitaire de Nîmes
name: Stéphane Droupy, MD PhD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT02383654: Compassionate Treatment : An Exploratory Clinical Trial to Assess Treatment of Amyotrophic Lateral Sclerosis
Official title: An Exploratory Clinical Trial to Assess Treatment of Amyotrophic Lateral Sclerosis With Brain Transplants of Autologous Adipose-Tissue Derived Stem Cells (ADSCs)
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
Conditions: Amyotrophic Lateral Sclerosis
Keywords: Amyotrophic Lateral Sclerosis
Autologous Adipose-Tissue Derived Stem Cells (ADSCs)
Lead sponsor: China Medical University Hospital
Sponsor class: OTHER
First posted: 2015-03-09
Enrollment: 1
Sex: MALE
Minimum age (years): 35
Maximum age (years): 50
Standard ages: ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: The purpose of the study is to determine the safety and possible effectiveness of Autologous Adipose-Tissue Derived Stem Cells treatment in a Amyotrophic Lateral Sclerosis(ALS) patient.

Detailed description: This pilot clinical trial is design to see the safety and possible efficiency of ADSCs treatment in a ALS patient. one subjects will be treated (n=1). The patient will receive brain transplantation of ADSCs and combines intravenous infusion ADSCs 4 times. Subjects will be assessed by adverse effects and functional outcomes of clinical: PI max , PE max,and Haloscale respiration, ALS functional rating scale (ALS-FRS) are analyzed at 1 month, 3 months, 6 months 9 months and 12 months.

Brain MRI scans will be obtained before and after the treatment. Long term follow-up will be performed at 1, 6 , and 12months for safety reasons. Brain CT for check operation safety before and after brain implantation.

Timing of Study: 12months recruitment period after approvals

Eligibility criteria: Compassionate Treatment

The number of participants for a person.

The patients (Guo XX) of 28% of lung function assessment (normal lung function was greater than 80%), the daily life of motor function score was 17 points (normal function score of 40 points).

Primary outcomes:
measure: changes of ALS-FRS score
timeFrame: Baseline-Day 28-Day 44-Day 60-6 months-9months-12months
measure: changes of respiratory function
timeFrame: Baseline-Day 28-Day 44-Day 60-6 mouths-9mouths-12mouths
measure: changes of neurologic function
timeFrame: Baseline-Day 28-Day 44-Day 60-6 mouths-9mouths-12mouths
Secondary outcomes:
measure: changes of brain structure
timeFrame: Baseline-Day 60- 6 mounths-12 mounths
Other outcomes:
Locations:
city: Beigang
country: Taiwan
facility: China Medical University Beigang Hospital
state: Yunlin
Study officials:
affiliation: China Medical University Beigand Hospital, Taiwan
name: Shinn-Zong Lin, M.D.;PhD.
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT02897154: Clinical Evaluation of i-STAT Analyzer Glucose, Hematocrit and Sodium for Capillary Samples
Official title: Clinical Evaluation of i-STAT Analyzer for Glucose, Hematocrit and Sodium
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Analytical Performance of Sodium, Glucose and Hematocrit Assays by the i-STAT 500 (Alinity) Analyzer
Lead sponsor: Abbott Point of Care
Sponsor class: INDUSTRY
First posted: 2016-09-13
Enrollment: 297
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Observational model: OTHER
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Adults (18 years or older)

Brief summary: The objective of this study is to compare the performance of two i-STAT Analyzers in a Point-of-Care (POC) setting. The evaluation will be performed using a cartridge to test glucose, hematocrit and sodium on capillary specimens.

Detailed description: The clinical performance for glucose, hematocrit and sodium assays for capillary samples was evaluated for the investigational i-STAT 500 (Alinity) analyzer based on results of method comparison testing against the i-STAT 1W analyzer.

Eligibility criteria: Inclusion Criteria:

* Subject is ≥ 18 years of age
* Subjects (or their legal representative) who are willing to voluntarily consent to the study

Exclusion Criteria:

* There are no exclusion criteria

Primary outcomes:
measure: Glucose (mg/dL) levels
timeFrame: Patient's blood is tested within 3 minutes of blood collection
measure: Hematocrit (%PCV) levels
timeFrame: Patient's blood is tested within 3 minutes of blood collection
measure: Sodium (mmol/L) levels
timeFrame: Patient's blood is tested within 3 minutes of blood collection
Secondary outcomes:
Other outcomes:
Locations:
city: Walnut Creek
country: United States
facility: Diablo Clinical Research
state: California
city: Louisville
country: United States
facility: Kentucky Clinical Trials Laboratory
state: Kentucky
city: Cleveland
country: United States
facility: Cleveland Clinic
state: Ohio
Study officials:
affiliation: Abbott Point of Care
name: Chris P Edwards, BSc
role: STUDY_DIRECTOR
References:
Clinical trial NCT03896854: CART-19 T Cell in CD19 Positive Relapsed or Refractory Acute Myeloid Leukemia (AML)
Official title: Pilot Study of the Efficacy and Safety of CD19 Targeted Chimeric Antigen Receptor Engineered T Cell in the Treatment of Relapsed or Refractory CD19 Positive Acute Myeloid Leukemia (AML)
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: PHASE1
PHASE2
Conditions: Acute Myeloid Leukemia
Lead sponsor: Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd
Sponsor class: INDUSTRY
First posted: 2019-04-01
Enrollment: 15
Sex: ALL
Minimum age (years): 6
Maximum age (years): 65
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: This is a single center, open-label phase 1/2 study to evaluate the safety and efficacy of targeted CD19 chimeric antigen receptor engineered T cell immunotherapy (CART) in the treatment of CD19 positive relapsed or refractory acute myeloid leukemia.

Detailed description: The patients will receive infusion of CART cells targeting CD19 to confirm the safety and efficacy of CD19 CART Cells in relapsed or refractory acute myeloid leukemia.

Eligibility criteria: Inclusion Criteria:

* Male or female patients with CD19+ relapsed/refractory acute myeloid leukemia
* Age 6-65 years.
* Left ventricular ejection fractions≥ 0.5 by echocardiography.
* Creatinine \< 1.6 mg/dL.
* Aspartate aminotransferase/aspartate aminotransferase \< 3x upper limit of normal.
* Bilirubin \<2.0 mg/dL.
* Karnofsky performance status ≥ 60
* Expected survival time ≥ 3 months (according to investigator's judgement)

Exclusion Criteria:

* Pregnant or lactating women.
* Uncontrolled active infection.
* Active hepatitis B or hepatitis C infection.
* Class III/IV cardiovascular disability according to the New York Heart Association Classification.
* HIV infection.
* Patients with history of seizure
* Active central nervous system leukemia

Primary outcomes:
measure: Adverse events
timeFrame: 12 months
Secondary outcomes:
Other outcomes:
Locations:
city: Suzhou
country: China
facility: The First Affiliated Hospital of Soochow University
state: Jiangsu
Study officials:
affiliation: The First Affiliated Hospital of Soochow University
name: Xiaowen Tang, Ph.D.
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT03704454: The Use of Pycnogenol® to Alleviate Menopausal Symptoms Induced or Increased by Breast and Gynecological Cancer Treatments
Official title: The Use of Pycnogenol® to Alleviate Menopausal Symptoms Induced or Increased by Breast and Gynecological Cancer Treatments
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Climacteric; Menorrhagia, Menopausal
Menopause
Lead sponsor: Legacy Health System
Sponsor class: OTHER
First posted: 2018-10-12
Enrollment: 40
Sex: FEMALE
Minimum age (years): 18
Maximum age (years): 99
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: CROSSOVER
Primary purpose: TREATMENT

Brief summary: This is a pilot study to test whether PYC can improve climacteric symptoms for women who have experienced either surgically or medically induced menopause as part of their treatment for breast or gynecologic cancers.


Eligibility criteria: Inclusion Criteria:

* Patient currently is undergoing treatment for cancer
* Patient has menopausal symptoms induced either by surgical or medical (patient on tamoxifen or aromatase inhibitor) interventions for cancer
* \> 18 years of age
* Willing to travel to a Legacy Health facility if necessary
* Agree to attend study visits outside of standard of care visits, if needed
* Willing to stop other supplements or medications that are aimed at treating menopausal symptoms at least 7 days before beginning study treatment
* Willing to engage in pre/post testing and survey/phone calls

Exclusion Criteria:

* Patient is currently undergoing chemotherapy treatment
* \< 18 years of age
* Unable to comply with protocol
* Unable to provide written informed consent
* Investigator does not believe study participation is in the best interest of the patient
* Patient had concurrent menopausal symptoms prior to the start of cancer treatment
* Menopausal symptoms are unrelated to surgical or medical treatment of breast or gynecologic cancers

Primary outcomes:
measure: Menopause Rating Scale (MRS)
timeFrame: The MRS will be administered at baseline, after 4 weeks, after 8 weeks, 2 week follow-up (10 weeks), and 1 month follow up (12 weeks) with the intention of calculating DFB score at each time point.
Secondary outcomes:
Other outcomes:
Locations:
city: Gresham
country: United States
facility: Legacy Mt. Hood Medical Center
state: Oregon
city: Portland
country: United States
facility: Legacy Good Samaritan Medical Center
state: Oregon
city: Tualatin
country: United States
facility: Legacy Meridian Park Medical Center
state: Oregon
Study officials:
affiliation: Legacy Health
name: Reza Antoszewska, NP-C
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT00358254: Noninvasive Skin Spectroscopy for Diabetes Screening
Official title: Noninvasive Skin Spectroscopy for Diabetes Screening
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Prediabetic State
Diabetes Mellitus, Type 2
Lead sponsor: InLight Solutions
Sponsor class: INDUSTRY
Collaborators: name: VeraLight, Inc.
First posted: 2006-07-31
Enrollment: 1000
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Observational model: COHORT
Time perspective: CROSS_SECTIONAL
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Those at risk for diabetes

Brief summary: The objective of this study is to assess the performance of a noninvasive device for the early screening of Diabetes Mellitus.

Detailed description: Approximately 18 million people have Type II diabetes, and of these, an estimated thirty-five percent are unaware of their condition. This translates to roughly 6.3 million undiagnosed cases worldwide in 2002. Many diagnoses are made years after the onset of the disease. This allows progression of the vascular lesions that arise during the time of uncontrolled glucose levels. As a result, microvascular retinopathy, nephropathy, and neuropathy are on the rise, as well as macrovascular complications such as: coronary heart disease, and cerebral vascular accidents. The prevalence and trends of diabetes underscore the need for effective and widespread screening. Our fluorescence based system under development will noninvasively measure skin glycation end products that are known to be strongly correlated with diabetes status and complications. Since the test would be painless and require no patient fasting, significant obstacles to screening compliance would be mitigated. The system offers hope for a screening test that is more sensitive and specific than the invasive tests currently used for diabetes screening (Oral Glucose Tolerance Test (OGTT) and the Fasting Plasma Glucose (FPG) test).

Eligibility criteria: Inclusion Criteria:

* Volunteers without Diabetes.
* Volunteers at risk for developing Type II diabetes.
* 18 years of age and older.

Exclusion Criteria:

* Under 18 years of age.
* Those diagnosed with Diabetes.

Primary outcomes:
Secondary outcomes:
Other outcomes:
Locations:
city: Albuquerque
country: United States
facility: InLight Solutions
state: New Mexico
city: Albuquerque
country: United States
facility: Tricore Reference Laboratory- Presbyterian Professional Building
state: New Mexico
Study officials:
affiliation: UNMHSC
name: Mark Rohrscheib, M.D.
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT00251654: Complications and Adverse Effects in Continuous Peripheral Regional Anesthesia
Official title: Complications and Adverse Effects in Continuous Peripheral Regional Anesthesia Results of Investigations on 3,491 Catheters
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Infection
Inflammation
Adverse Effects
Keywords: complications
adverse events
regional anesthesia
adverse effects
Lead sponsor: Rechbergklinik Bretten
Sponsor class: OTHER
Collaborators: name: BG Unfallklinik Murnau
First posted: 2005-11-10
Enrollment: 9000
Sex: ALL
Minimum age (years): 1
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: All patients receiving perineural blocks via catheter ASA 1 to 4

Brief summary: The investigators prospectively document infectious, neurological, and other complications or adverse events occurring during peripheral regional anesthesia via a catheter using computer-based data recording.

Detailed description: Perineural blocks with catheter placement are more and more frequently used. Few data dealing with infectious complications of perineural catheters exist. We assess incidence and localization of infectious complications of perineural catheters by means of computerized data acquisition. We prospectively evaluate perineural catheters placed at different sites for regional anesthesia and postoperative analgesia. The catheters were placed under standardized sterile conditions by using the nerve stimulator technique. Local inflammation is defined as the presence of at least two of the three signs: redness, pain on pressure or swelling. Infection is defined as the presence of at least two of the following criteria: pus at the catheter insertion site, fever, increased CRP and/or leukocytes requiring antibiotic therapy.

Eligibility criteria: Inclusion Criteria:

* All patients receiving perineural blocks via catheter

Exclusion criteria:

* None

Primary outcomes:
Secondary outcomes:
Other outcomes:
Locations:
city: Murnau
country: Germany
facility: BG Unfallklinik
state: Bayern
Study officials:
affiliation: BG Unfallklinik Murnau
name: Johannes Büttner, MD
role: STUDY_CHAIR
References:
citation: Neuburger M, Breitbarth J, Reisig F, Lang D, Buttner J. [Complications and adverse events in continuous peripheral regional anesthesia Results of investigations on 3,491 catheters]. Anaesthesist. 2006 Jan;55(1):33-40. doi: 10.1007/s00101-005-0920-4. German.
citation: Neuburger M, Buttner J, Blumenthal S, Breitbarth J, Borgeat A. Inflammation and infection complications of 2285 perineural catheters: a prospective study. Acta Anaesthesiol Scand. 2007 Jan;51(1):108-14. doi: 10.1111/j.1399-6576.2006.01173.x. Epub 2006 Nov 1.
citation: Neuburger M, Reisig F, Zimmermann L, Buttner J. [Infection control in continuous peripheral regional anesthesia. Clinical study on disinfection time and subcutaneous tunneling in interscalene plexus anesthesia]. Anaesthesist. 2009 Aug;58(8):795-9. doi: 10.1007/s00101-009-1586-0. German.